bluebird bio Inc (BLUE)
0.953
-0.01
(-1.07%)
USD |
NASDAQ |
Apr 18, 16:00
0.9568
0.00 (0.00%)
After-Hours: 20:00
bluebird bio Research and Development Expense (Quarterly): 45.46M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 45.46M |
| June 30, 2023 | 42.27M |
| March 31, 2023 | 46.14M |
| December 31, 2022 | 45.90M |
| September 30, 2022 | 53.15M |
| June 30, 2022 | 63.84M |
| March 31, 2022 | 77.88M |
| December 31, 2021 | 79.38M |
| September 30, 2021 | 73.68M |
| June 30, 2021 | 84.64M |
| March 31, 2021 | 82.84M |
| December 31, 2020 | -131.55M |
| September 30, 2020 | 140.43M |
| June 30, 2020 | 156.31M |
| March 31, 2020 | 154.12M |
| December 31, 2019 | -93.47M |
| September 30, 2019 | 151.41M |
| June 30, 2019 | 146.54M |
| March 31, 2019 | 122.64M |
| December 31, 2018 | 119.72M |
| September 30, 2018 | 116.74M |
| June 30, 2018 | 115.01M |
| March 31, 2018 | 97.11M |
| December 31, 2017 | 92.58M |
| Date | Value |
|---|---|
| September 30, 2017 | 61.54M |
| June 30, 2017 | 63.89M |
| March 31, 2017 | 55.03M |
| December 31, 2016 | 57.13M |
| September 30, 2016 | 63.97M |
| June 30, 2016 | 41.76M |
| March 31, 2016 | 41.91M |
| December 31, 2015 | 35.66M |
| September 30, 2015 | 30.40M |
| June 30, 2015 | 44.27M |
| March 31, 2015 | 23.72M |
| December 31, 2014 | 20.53M |
| September 30, 2014 | 16.65M |
| June 30, 2014 | 13.93M |
| March 31, 2014 | 11.46M |
| December 31, 2013 | 9.765M |
| September 30, 2013 | 8.706M |
| June 30, 2013 | 7.247M |
| March 31, 2013 | 5.284M |
| December 31, 2012 | 6.497M |
| September 30, 2012 | 3.501M |
| June 30, 2012 | 3.354M |
| March 31, 2012 | 3.858M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-131.55M
Minimum
Dec 2020
156.31M
Maximum
Jun 2020
67.72M
Average
75.78M
Median
Research and Development Expense (Quarterly) Benchmarks
| Agenus Inc | -- |
| Motus GI Holdings Inc | 0.561M |
| Tivic Health Systems Inc | 0.36M |
| Vertex Pharmaceuticals Inc | 824.60M |
| AIM ImmunoTech Inc | 3.20M |